Oryzon Genomics SA has appointed Douglas Faller, a clinical haematologist, as global chief medical officer, based in Boston, US. Dr Faller will help the Spanish company strengthen its links with US hospitals and research institutions in order to advance candidate drugs for cancer and diseases of the central nervous system.
Dr Faller joins Oryzon from Takeda Pharmaceutical Co Ltd where he was medical director for more than five years. He holds a medical degree from Harvard University and a PhD in cancer molecular biology from the Massachusetts Institute of Technology, US. In addition to founding and directing the Boston University Cancer Center, Dr Faller has launched several biotech companies, some of which are currently listed on Nasdaq.
Oxyzon announced the appointment on 28 March 2022.
Copyright 2022 Evernow Publishing Ltd